These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35299705)

  • 41. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
    Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
    Elife; 2020 Mar; 9():. PubMed ID: 32151314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Orthotopic heart transplant facilitated autologous hematopoietic stem cell transplantation in light-chain amyloidosis.
    Kamble RT
    Methodist Debakey Cardiovasc J; 2012; 8(3):17-8. PubMed ID: 23227280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New and developing therapies for AL amyloidosis.
    Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
    Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Prevalence and Management of Systemic Amyloidosis in Western Countries.
    Nienhuis HL; Bijzet J; Hazenberg BP
    Kidney Dis (Basel); 2016 Apr; 2(1):10-9. PubMed ID: 27536687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insight from an autopsy in a patient with rapidly worsening heart failure due to amyloid light-chain cardiac amyloidosis: A case report.
    Yokoyama H; Shishido K; Ito J; Kamata W; Katoh N; Saito S
    J Cardiol Cases; 2020 Aug; 22(2):48-51. PubMed ID: 32774518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
    Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bilateral kidney infarction due to primary Al amyloidosis: a first case report.
    Mihout F; Joseph L; Brocheriou I; Leblond V; Varnous S; Ronco P; Plaisier E
    Medicine (Baltimore); 2015 May; 94(17):e777. PubMed ID: 25929920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.
    Gillmore JD; Goodman HJ; Lachmann HJ; Offer M; Wechalekar AD; Joshi J; Pepys MB; Hawkins PN
    Blood; 2006 Feb; 107(3):1227-9. PubMed ID: 16210334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amyloid light-chain amyloidosis presenting as abdominal bloating: a case report.
    Lee ASY; Lee DZQ; Vasanwala FF
    J Med Case Rep; 2016 Mar; 10():68. PubMed ID: 27026530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis.
    Kristen AV; Brokbals E; Aus dem Siepen F; Bauer R; Hein S; Aurich M; Riffel J; Behrens HM; Krüger S; Schirmacher P; Katus HA; Röcken C
    J Am Coll Cardiol; 2016 Jul; 68(1):13-24. PubMed ID: 27364045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
    Arbustini E; Gavazzi A; Merlini G
    Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China.
    Huang XH; Liu ZH
    Kidney Dis (Basel); 2016 Apr; 2(1):1-9. PubMed ID: 27536686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
    Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K
    Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.
    Schönland SO; Dreger P; de Witte T; Hegenbart U
    Bone Marrow Transplant; 2012 Jul; 47(7):895-905. PubMed ID: 21785469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
    Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
    Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis.
    Fine NM; Davis MK; Anderson K; Delgado DH; Giraldeau G; Kitchlu A; Massie R; Narayan J; Swiggum E; Venner CP; Ducharme A; Galant NJ; Hahn C; Howlett JG; Mielniczuk L; Parent MC; Reece D; Royal V; Toma M; Virani SA; Zieroth S
    Can J Cardiol; 2020 Mar; 36(3):322-334. PubMed ID: 32145862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms.
    Korosoglou G; Giusca S; André F; Aus dem Siepen F; Nunninger P; Kristen AV; Frey N
    Vasc Health Risk Manag; 2021; 17():661-673. PubMed ID: 34720583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management.
    Estep JD; Bhimaraj A; Cordero-Reyes AM; Bruckner B; Loebe M; Torre-Amione G
    Methodist Debakey Cardiovasc J; 2012; 8(3):8-16. PubMed ID: 23227279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.